Johnson & Johnson (NYSE:JNJ) 주식

JOHNSON & JOHNSON

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

Coinbase Photo by Useacoin on Shutterstock

Equities

Large Cap

News

Movers

Trading Ideas

AAPL

ADBE

COIN

EXPE

GMAB

HOOD

IBKR

SAIL

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요? 1. 테라다인(NASDAQ:TER)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 비공개 금액에 인수하기로 합의했다. 애널리스트들은 이 회사의 가격 전망을 하향 조정했다.

코인베이스, 애플, 로빈후드 등 지난주 급락한 대형주 12종목 (3월 10일-3월 14일)

Markets

DLTR

FTAI

Hims & Hers Health, Inc. Class A Common Stock

HIMS

NVDA

PHIG

PYPL

SMCI

SOFI

TMUS

월요일(3일) 미국 증시는 도널드 트럼프 대통령이 전면적인 새로운 관세를 발표하면서 급격한 매도세를 보였고, 지난주 손실이 확대되며 모든 주요 섹터가 하락세를 보였다. 

트럼프 관세로 인한 시장 매도세 속 기술 부문 큰 타격...엔비디아·슈퍼마이크로·ARM 급락

chart ai3

Tech

$BTC

AMGN

AMZN

BABA

SPDR Dow Jones Industrial Average ETF Trust

GOOG

GOOGL

KWEB

MCHI

MSFT

TSLA

XPEV

최근 몇 년 동안 성과가 좋았던 상위 주식과 자산들이 2025년 초에 주춤거리고 있다. 비트코인(CRYPTO: BTC)은 3개월 최저가로 떨어졌다.
2024년 상위 자산들의 연초 성과와 이들을 초과 성과내고 있는 자산들을 살펴보겠다.

2025년 중국 ETF 및 다우 주식의 상위 성과로, 비트코인과 매그 7이 안전 자산의 지위 상실

Biotech

General

MRNA

President Trump Says Will Be Announcing Pharma Tariffs Soon

Johnson &amp; Johnson&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Phase 3 MARIPOSA study</a>.
Head-to-head comparison data versus AstraZeneca Plc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Tagrisso (osimertinib) showed Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) significantly extended OS in the first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) <a href="https://www.benzinga.com/pressreleases/25/03/n44497192/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-outperforms-osimertinib-with-a-significant-and" target="_blank" rel="noreferrer noopener">or L858R substitution mutations</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" rel="noreferrer noopener">Pharmaceutical Firms Say UK Investment Is &#8216;Unlikely&#8217; Unless Payment Levy Is Addressed</a>
Johnson &amp; Johnson said in a Wednesday press release that the median OS is projected to exceed one year beyond the median of three years observed with&nbsp;osimertinib and has not yet been reached.
The pharma giant says this is the first and only study to show a statistically significant and clinically meaningful OS improvement over osimertinib.
At a median follow-up of 37.8 months, patients treated with the chemotherapy-free regimen of first-line Rybrevant plus Lazcluze had a significantly longer OS than those receiving osimertinib.
Median OS for Rybrevant plus Lazcluze has not yet been reached, indicating that survival benefits continue to extend beyond the measured follow-up period.
Comparatively, median OS for osimertinib-treated patients was 36.7 months.
56% of patients treated with Rybrevant plus Lazcluze were alive at three and a half years, compared to 44% of patients on osimertinib.
The Rybrevant plus Lazcluze combination also prolonged multiple secondary endpoints vs. osimertinib, including intracranial PFS, intracranial duration of response (DOR) and intracranial overall response rate (ORR).&nbsp;
Rybrevant plus Lazcluze prolonged the time to symptomatic progression—the time from treatment randomization to the onset of lung cancer symptoms—by more than 14 months compared to osimertinib (43.6 months vs. 29.3 months).
The MARIPOSA study&nbsp;<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4389728-1&amp;h=3239710368&amp;u=https%3A%2F%2Fwww.jnj.com%2Fmedia-center%2Fpress-releases%2Flandmark-phase-3-mariposa-study-shows-rybrevant-amivantamab-vmjw-plus-lazertinib-resulted-in-30-percent-reduction-in-risk-of-disease-progression-or-death-compared-to-osimertinib-in-patients-with-egfr-mutated-non-small-cell-lung-cancer&amp;a=met+its+primary+endpoint" rel="noreferrer noopener">met its primary endpoint</a> in October 2023, showing a statistically significant and clinically meaningful improvement in PFS compared to osimertinib.&nbsp;
Rybrevant plus Lazcluze is approved in&nbsp;the United States,&nbsp;Europe&nbsp;, and other markets worldwide for patients with first-line&nbsp;EGFR-mutated NSCLC.
Price Action: JNJ stock is up 0.58% at $161.96 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44493472/whats-going-on-with-electronics-maker-kopins-stock-today" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Electronics Maker Kopin&#8217;s Stock Today?</a></li>
</ul>
Photo: Shutterstock

Health Care

J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study

Median overall survival not yet reached with projected improvement of more than one year versus osimertinib
RARITAN, N.J., March 26, 2025 /PRNewswire/ --&nbsp;Johnson &amp; Johnson&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced results for the gold standard endpoint in cancer treatment of overall survival (OS) from the Phase 3 MARIPOSA study. Head-to-head comparison data versus osimertinib showed RYBREVANT&#xAE; (amivantamab-vmjw) plus LAZCLUZE&#x2122; (lazertinib) significantly extended OS in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. Median OS is projected to exceed one year beyond the median of three years observed with&nbsp;osimertinib and has not yet been reached. This is the first and only study to show a statistically significant and clinically meaningful OS improvement over osimertinib. New compelling data were presented during a proffered paper session at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4389728-1&amp;h=3103798463&amp;u=https%3A%2F%2Fwww.esmo.org%2Fmeeting-calendar%2Feuropean-lung-cancer-congress-2025&amp;a=2025+European+Lung+Cancer+Congress+(ELCC)">2025 European Lung Cancer Congress (ELCC)</a> (Abstract #4O).1

Johnson & Johnson Announces Results For The Gold Standard Endpoint In Cancer Treatment Of Overall Survival From The Phase 3 MARIPOSA Study; Median Overall Survival Not Yet Reached With Projected Improvement Of More Than One Year Versus Osimertinib

Oral presentation features new data from the 24-week pivotal Vivacity-MG3 study which show sustained disease control through treatment with nipocalimab on the clinician-assessed QMGa score in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+
Nipocalimab data demonstrate longer-term sustained disease control as measured by MG-ADLb and QMG scores from the ongoing open-label extension (OLE) of the Vivacity-MG3 study
Johnson &amp; Johnson filed a Biologics License Application (BLA) for nipocalimab in August 2024 and was granted U.S. FDA Priority Review for the treatment of gMG&nbsp;
Real-world studies highlight the unmet need of patients living with gMG, including those who are pregnant or receiving steroids
SPRING HOUSE, Pa., March 26, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today that 12 abstracts, including two oral presentations, highlighting the Company's innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia gravis (gMG), will be presented at the 2025 American Academy of Neurology (AAN) Annual Meeting from April 5 – 9 in San Diego, California.

Johnson & Johnson Presents New Nipocalimab Data And Real-World Research At AAN 2025 Highlighting Phase 3 Results And Commitment To People Living With Generalized Myasthenia Gravis

The Association of the British Pharmaceutical Industry (ABPI) is urging ministers to address excessive levies on manufacturers to ensure the sector remains competitive globally.
The life sciences industry, a key pillar of the UK&#8217;s economic strategy, could struggle to attract investment unless payment rates are adjusted.
Last week, the government <a href="https://www.abpi.org.uk/media/news/2025/march/uk-set-to-demand-a-third-of-pharmaceutical-company-revenue-in-second-half-of-2025/" target="_blank" rel="noreferrer noopener">proposed</a> raising the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies&#8217; National Health Service (NHS) sales in the second half of 2025.
The payment rate is the revenue companies must hand back to the government on their sales of branded medicines to the NHS. It is an additional charge to the taxes paid by companies.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44362710/uk-pharma-industry-trade-association-restores-wegovyozempic-maker-novo-nordisks-membership-after-two-years-of-suspension" rel="noreferrer noopener">UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk&#8217;s Membership After 2 Years Of Suspension</a>
UK pharmaceutical leaders from Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), Boehringer Ingelheim, Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), Daiichi Sankyo Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>), Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), Takeda Pharmaceutical Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) and UCB SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>) point to the challenges to investing in the U.K.
The pharmaceutical sector <a target="_blank" href="https://www.abpi.org.uk/media/news/2025/march/medicine-levy-makes-the-uk-un-investable-say-pharma-leaders/" rel="noreferrer noopener">contributes</a> over 17.6 billion pounds ($22.76 billion) directly to the U.K. economy, with an additional 45 billion generated through research and development spillovers.
However, companies argue that growth is being stifled due to escalating mandatory payments. Under the current system, firms must pay between 23.5% and 35.6% of their branded medicine sales revenue to the NHS. This is significantly higher than other European nations, where comparable rates range from 5.7% to 9%, ABPI writes.
The ABPI report highlights that while the UK once led in medicine availability, it has slipped to ninth place in Europe over the past decade. One year after launch, medicine usage in England is only 52% of the average of comparable nations, rising to 62% after five years.
Additionally, the UK has dropped from fourth to tenth in global rankings for phase 3 clinical trials, lagging behind Spain, Germany and Italy.
Investment in UK pharmaceutical research has also declined, with the country&#8217;s share of global R&amp;D investment falling from 7.3% to 5.7% in just three years.
This marks the fastest decline of any European G7 nation. Meanwhile, NHS funding has grown by 33% in real terms over the past decade, but spending on branded medicines has been capped at annual growth rates between 1.1% and 2%, declining by 11% when adjusted for inflation.
The industry and government have long collaborated on agreements to ensure NHS access to medicines.
The latest, the Voluntary Scheme for Branded Medicines, Pricing, Access, and Growth (VPAG), was intended to realign UK payment rates with international standards. While rates for newer medicines briefly dropped to 15.1% in 2024, they surged again in 2025 to 23.5% for newer medicines, with companies still paying 10.6%-35.6% for older products.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44436766/is-freeport-mcmorans-us-based-footprint-an-advantage-analyst-upgrades-stock-amid-copper-import-tariff-risk" target="_blank" rel="noreferrer noopener">Is Freeport-McMoRan&#8217;s US-Based Footprint An Advantage? Analyst Upgrades Stock Amid Copper Import Tariff Risk</a></li>
</ul>
Photo: Shutterstock

Government

Eurozone

BIIB

DSNKY

GILD

RHHBY

UCBJF

UCBJY

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed

On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson &amp; Johnson&#8217;s (NYSE&nbsp;JNJ) Tremfya&nbsp;(guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (IV) induction options, for adults with moderately to severely active Crohn&#8217;s disease (CD), a chronic inflammatory condition <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">of the gastrointestinal tract</a>.
This approval is supported by results from multiple Phase 3 trials evaluating more than 1,300 patients with moderately to severely active CD who failed or were intolerant to conventional therapy or biologics.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44380787/fda-grants-fast-track-review-to-johnson-johnsons-nipocalimab-for-autoimmune-disorder-that-affects-tears-saliva" rel="noreferrer noopener">FDA Grants Fast Track Review To Johnson &amp; Johnson&#8217;s Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva</a>
The GRAVITI study evaluated Tremfya&nbsp;SC induction and maintenance <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44427657/u-s-fda-approves-tremfya-guselkumab-the-first-and-only-il-23-inhibitor-offering-both-subcutaneous-" rel="noreferrer noopener">therapy versus placebo</a>.&nbsp;
Data from the GALAXI clinical program showed that Tremfya&nbsp;was superior to the company&#8217;s Stelara&nbsp;in all pooled endoscopic endpoints.
This approval marks the fourth indication for Tremfya in the U.S., following moderate-to-severe plaque psoriasis in&nbsp;July 2017, active psoriatic arthritis in July 2020, and moderately to severely active ulcerative colitis (UC) in&nbsp;September 2024.
In November 2024,&nbsp;Johnson &amp; Johnson&nbsp;<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4388053-1&amp;h=486347295&amp;u=https%3A%2F%2Fwww.jnj.com%2Fmedia-center%2Fpress-releases%2Fjohnson-johnson-seeks-u-s-fda-approval-for-subcutaneous-induction-regimen-of-tremfya-guselkumab-in-ulcerative-colitis-a-first-for-an-il-23-inhibitor&amp;a=submitted&amp;tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1Vco2-XEnaS03LIXMO-ISg" rel="noreferrer noopener">submitted</a> a supplemental Biologics License Application (sBLA) to the FDA seeking approval of an SC induction regimen of Tremfya&nbsp;for adults with moderately to severely active UC based on the results of the Phase 3 ASTRO study.
In 2024, Tremfya generated sales of $3.67 billion, <a target="_blank" href="https://www.benzinga.com/25/01/43125966/johnson-johnson-reports-q4-earnings-above-wall-street-estimates-driven-by-strong-cancer-drugs-revenue" rel="noreferrer noopener">up 17% year over year</a>.
Price Action: JNJ stock is down 0.15% at $162.77 during the premarket session at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson To Invest $55 Billion In US To Boost Manufacturing, Drug Discovery</a></li>
</ul>
Photo via Shutterstock

FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease

Pharmaceutical and medical technology giant Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) plans to invest more than <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44432210/johnson-johnson-increases-u-s-investment-to-more-than-55-billion-over-the-next-four-years" rel="noreferrer noopener">$55 billion in the U.S. over the next four years.</a>
This initiative, designed to strengthen American manufacturing, R&amp;D, and technological advancements, represents a 25% rise from previous four-year funding levels.
As part of the investment, the company will broaden its presence in the U.S. with the establishment of new facilities and job opportunities.
Johnson &amp; Johnson&#8217;s investment will fund the creation of three new manufacturing facilities, along with the expansion of existing ones in the company&#8217;s Innovative Medicine and MedTech divisions.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44359600/hyperfine-nvidia-partner-to-make-brain-mris-more-affordable" rel="noreferrer noopener">Hyperfine, Nvidia Partner To Make Brain MRIs More Affordable</a>
Additionally, Johnson &amp; Johnson is expanding its technological and research infrastructure to accelerate drug discovery and advancement in areas like oncology, immunology, and robotics.
&#8220;Today&#8217;s announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world&#8217;s toughest healthcare challenges,&#8221; said Chairman and Chief Executive Officer Joaquin Duato.
&#8220;Our increased U.S. investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add U.S.-based jobs but manufacture cutting edge medicines to treat patients in America and around the world.&#8221;
Johnson &amp; Johnson is holding a groundbreaking event in Wilson, North Carolina today, to begin construction of a $2 billion, 500,000-square-foot biologics manufacturing plant.
This facility will be used to produce advanced medicines for diseases like cancer and neurological conditions. Once completed, the plant is anticipated to generate 5,000 jobs during its construction phase and create more than 500 permanent positions. Additionally, the project is expected to contribute $3 billion to North Carolina&#8217;s economy over the first ten years.
The company&#8217;s economic impact in the U.S. is estimated to exceed $100 billion annually.
In January, the company <a target="_blank" href="https://www.benzinga.com/25/01/43125966/johnson-johnson-reports-q4-earnings-above-wall-street-estimates-driven-by-strong-cancer-drugs-revenue" rel="noreferrer noopener">reported a 5.3% sales increase </a>to $22.52 billion and an adjusted EPS of $2.04 for the fourth quarter, both above the consensus estimates.
Price Action: JNJ shares traded lower by 0.15% at $162.77 in premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44420034/d-waves-new-blockchain-architecture-could-slash-energy-usage-by-1000x" target="_blank" rel="noreferrer noopener">D-Wave Unveils New Blockchain Architecture To Slash Energy Usage</a></li>
</ul>
Image via Shutterstock.

Johnson & Johnson To Invest $55 Billion In US To Boost Manufacturing, Drug Discovery

This represents a 25% increase in investment compared to the previous four years and builds upon the Company's already elevated U.S. investment levels resulting from the passage of the 2017 Tax Cuts &amp; Jobs Act.

Johnson & Johnson Plans Manufacturing, R&D And Technology Investments Of More Than $55B In US Over Next Four Years

<ul>
<li>TREMFYA&#xAE; is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen</li>
<li>Supported by data from the GALAXI study, TREMFYA&#xAE; is the only IL-23i to show superiority versus STELARA&#xAE;&nbsp;in all pooled endoscopic endpoints within a double-blinded registrational trial&nbsp;</li>
<li>TREMFYA&#xAE; approval in Crohn's disease builds upon recent ulcerative colitis FDA approval, marking the fourth indication for this dual-acting IL-23i in the U.S.</li>
</ul>

Reported Earlier, FDA Approves Johnson & Johnson's TREMFYA For Moderate To Severe Crohn's, First IL-23i With SC And IV Induction Options

Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) just hit <a href="https://www.benzinga.com/topic/golden-cross">a Golden Cross</a>, a classic bullish technical pattern that signals potential long-term upside. The stock's 50-day simple moving average crossed above its 200-day simple moving average, often seen as a sign of strengthening momentum.
While the charts suggest optimism, Johnson &amp; Johnson's latest breakthrough in lung cancer treatment could provide an additional catalyst for investors.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="618" height="487" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20113941/Screenshot-2025-03-20-at-9.08.56-PM.png" alt="" class="wp-image-834145" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20113941/Screenshot-2025-03-20-at-9.08.56-PM.png 618w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20113941/Screenshot-2025-03-20-at-9.08.56-PM-300x236.png 300w" sizes="(max-width: 618px) 100vw, 618px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
<h1 class="wp-block-heading">Johnson &amp; Johnson Stock: Bullish, But With Near-Term Hurdles</h1>
At $162.37, the Johnson &amp; Johnson stock price shows signs of strength, but short-term moving averages present a mixed picture. The eight-day simple moving average at $163.37 and the 20-day simple moving average at $164.45 suggest slight selling pressure. However, the 50-day simple moving average at $156.24 and the 200-day simple moving average at $155.72 firmly support a bullish trend.
The Moving Average Convergence Divergence (MACD) indicator at 1.74 reinforces the bullish outlook, while a Relative Strength Index (RSI) of 52.33 indicates the stock is in neutral territory — not overbought or oversold.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/03/44380787/fda-grants-fast-track-review-to-johnson-johnsons-nipocalimab-for-autoimmune-disorder-that-affects-tears-saliva">FDA Grants Fast Track Review To Johnson &amp; Johnson&#8217;s Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva</a>
<h1 class="wp-block-heading">Cancer Breakthrough Could Fuel Long-Term Gains</h1>
Beyond technicals, Johnson &amp; Johnson <a href="https://in.investing.com/news/company-news/johnson--johnson-announces-breakthrough-in-lung-cancer-treatment-93CH-4732368">announced</a> a major milestone in lung cancer treatment. The Phase 3 MARIPOSA study revealed that its RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) combination therapy significantly improved survival rates for patients with advanced non-small cell lung cancer. 
With the European Medicines Agency considering approval, this breakthrough could be a long-term revenue driver.
<h1 class="wp-block-heading">Investor Takeaway: A Strong Setup With Momentum</h1>
The Golden Cross suggests Johnson &amp; Johnson stock's long-term trend is turning bullish, but short-term resistance levels may test the stock's strength.
With a game-changing cancer treatment in the pipeline and technicals flashing bullish signals, investors have fundamental and technical reasons to keep Johnson &amp; Johnson on their radar.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/03/44383053/alpha-cognition-is-under-followed-as-alzheimer-drug-targets-2-billion-long-term-care-market-analyst">Alpha Cognition Is &#8216;Under-Followed&#8217; As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst</a></li>
</ul>
Photo: Shutterstock

Technicals

Signals

Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough

Events

Johnson & Johnson To Present Data At 2025 European Lung Cancer Congress Including Results From Phase 3 MARIPOSA Study Of RYBREVANT Plus LAZCLUZE vs Osimertinib

On Tuesday, HC Wainwright initiated coverage on Alpha Cognition Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>), noting a new twist on a tried-and-<a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">tested treatment paradigm</a>.
Alpha Cognition&#8217;s lead product, Zunveyl (benzgalantamine), is a prodrug of galantamine—a well-known, long-marketed acetyl cholinesterase inhibitor initially launched in the U.S. by Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) in 2001 under the trade name Reminyl (later changed to Razadyne in 2005).
In July 2024, the FDA approved Zunveyl under the 505(b)(2) pathway.
On Tuesday, Alpha Cognition announced the official commercial launch of Zunveyl, a new treatment for mild to moderate Alzheimer&#8217;s disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42873111/alpha-cognition-inks-44-million-licensing-pact-for-its-alzheimers-drug-in-china" rel="noreferrer noopener">Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer&#8217;s Drug In China</a>
The commercial strategy addresses the challenges of the long-term care market and the largest segment for Alzheimer&#8217;s disease. It&#8217;s also a <a href="https://www.benzinga.com/pressreleases/25/03/b44375080/alpha-cognition-announces-the-commercial-launch-of-zunveyl-benzgalantamine-for-the-treatment-of-mi" target="_blank" rel="noreferrer noopener">$2 billion market opportunity</a>.
Cholinesterase inhibitors (ChEIs) remain the most widely used anti-AD drugs. However, the existing marketed ChEIs are all associated with a significant incidence of gastrointestinal (GI) side effects (e.g., nausea, vomiting, and diarrhea) that typically occur in 30-40% of patients given these drugs.
Existing marketed ChEIs are also associated with a high incidence of sleep disturbances.
HC Wainwright writes the drug will be just as effective as the original molecule while offering better safety and tolerability. Analyst Raghuram Selvaraju estimates Alpha Cognition could reach $540 million in peak annual U.S. sales for Zunveyl by the late 2030s.
HC Wainwright has initiated with a Buy rating with <a target="_blank" href="https://www.benzinga.com/quote/ACOG/analyst-ratings" rel="noreferrer noopener">a price target of $20</a>.
The analyst expects Alpha Cognition to reach cash flow breakeven next year, driven by Zunveyl&#8217;s uptake.
Alpha Cognition&#8217;s share price has not increased in anticipation of the Zunveyl U.S. launch. The company is &#8220;comparatively under-followed,&#8221; Selvaraju wrote.
Alpha Cognition was originally listed on the Canadian Securities Exchange. It voluntarily delisted from that exchange in December 2024 after securing a NASDAQ listing.
Alpha Cognition&#8217;s modest &#8220;sub-$50M enterprise value&#8221; belies the company&#8217;s considerable long-term promise, Selvaraju added. 
The analyst expects Zunveyl uptake and market penetration metrics to drive favorable sentiment going forward.&#8221;
Price Action: ACOG stock is up 3.34% at $5.88 at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44380787/fda-grants-fast-track-review-to-johnson-johnsons-nipocalimab-for-autoimmune-disorder-that-affects-tears-saliva" target="_blank" rel="noreferrer noopener">FDA Grants Fast Track Review To Johnson &amp; Johnson&#8217;s Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva</a></li>
</ul>
Image: Shutterstock

Analyst Color

Initiation

Analyst Ratings

ACOG

Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst

The U.S. Food and Drug Administration granted on Tuesday Fast Track designation to Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) investigational nipocalimab for moderate-to-severe <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">Sjögren&#8217;s disease (SjD)</a>.
Last year, FDA granted Breakthrough Therapy designation (BTD) for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44374366/nipocalimab-the-first-and-only-investigational-treatment-to-be-granted-u-s-fda-breakthrough-therap" rel="noreferrer noopener">the investigational therapy</a>.
The Phase 2 DAHLIAS study, <a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4384625-1&amp;h=1495278526&amp;u=https%3A%2F%2Fwww.jnj.com%2Fmedia-center%2Fpress-releases%2Fnipocalimab-demonstrates-significant-clinical-improvement-in-disease-activity-and-igg-reduction-in-phase-2-sjogrens-disease-study&amp;a=results+of+which+were+presented+last+year" rel="noreferrer noopener">presented last year</a>, represented the first-ever positive results of an investigational FcRn blocker as a potential targeted therapy in SjD.&nbsp;
<a target="_blank" href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4384625-1&amp;h=1819366589&amp;u=https%3A%2F%2Fwww.jnj.com%2Fmedia-center%2Fpress-releases%2Flate-breaking-results-show-nipocalimab-significantly-improves-sjogrens-disease-activity-in-a-phase-2-study&amp;a=The+study" rel="noreferrer noopener">The study</a> achieved the primary endpoint in the 15 mg/kg Q2W nipocalimab group, showing a greater than 70% relative average improvement in systemic disease activity at Week 24 compared to placebo and IgG reductions of more than 77%.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44375773/cancer-focused-nanobiotix-adjusts-2-7-billion-johnson-johnson-agreement-to-strengthen-finances-and-relieve-funding-burden" rel="noreferrer noopener">Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson &amp; Johnson Agreement To Strengthen Finances And Relieve Funding Burden</a>
Trends of improvement were similarly observed across multiple secondary endpoints. Safety and tolerability were consistent with other nipocalimab clinical studies.
Sjögren&#8217;s disease, also known as Sjögren&#8217;s syndrome, is&nbsp;a chronic autoimmune disorder that primarily affects the body&#8217;s exocrine glands (or moisture-producing glands), particularly those responsible for producing tears and saliva, leading to dry eyes and mouth.
Earlier this month, Johnson &amp; Johnson decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa opioid receptor (KOR) antagonist, as an adjunctive treatment for major depressive disorder (aMDD). The move follows insufficient efficacy in the target patient population. The data confirmed aticaprant is safe and well-tolerated, and no new safety <a href="https://www.benzinga.com/25/03/44190052/johnson-johnson-stops-late-stage-depression-study-over-insufficient-efficacy" target="_blank" rel="noreferrer noopener">signals were identified</a>.
In February, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) and Johnson &amp; Johnson discontinued the E.mbrace phase 3 study evaluating a vaccine candidate for extraintestinal pathogenic E. coli. The companies determined that the vaccine candidate was not sufficiently effective at preventing invasive E. coli disease (IED) <a href="https://www.benzinga.com/general/biotech/25/02/43692253/sanofi-johnson-johnson-partnered-vaccine-against-bacterial-sepsis-flunks-late-stage-study" target="_blank" rel="noreferrer noopener">compared to placebo</a>.
JNJ Price Action: Johnson &amp; Johnson stock is up 0.71% at $164 at publication Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44378262/tesla-rival-zeekr-to-provide-free-advanced-driver-assistance-tech-in-china-report" target="_blank" rel="noreferrer noopener">Tesla Rival Zeekr To Provide Free Advanced Driver-Assistance Tech In China: Report</a></li>
</ul>
Photo: Gorodenkoff via Shutterstock

FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva

On Monday, Nanobiotix SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) announced an amendment to its global licensing agreement with Janssen Pharmaceutica NV, a Johnson &amp; Johnson company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), as part of <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">its financial strategy</a>.
The revision relieves Nanobiotix of funding obligations for its pivotal NANORAY-312 Phase 3 trial while modifying certain <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44364428/nanobiotix-strengthens-financial-position-through-amendment-of-global-licensing-agreement-for-jnj-" rel="noreferrer noopener">future milestone payments</a>.
The company expects the changes to bolster its financial stability and extend its cash runway.
Under the revised agreement, Johnson &amp; Johnson will assume nearly all remaining costs for NANORAY-312 through trial completion, with Nanobiotix covering only a small portion.
Also Read: <a href="https://www.benzinga.com/markets/forex/25/03/44372206/asia-and-europe-markets-gains-gold-makes-new-high-global-markets-today-while-us-slept" target="_blank" rel="noreferrer noopener">Asia And Europe Markets Gains, Gold Makes New High &#8211; Global Markets Today While US Slept</a>
This shift significantly reduces Nanobiotix's financial burden and allows the company to focus on advancing its clinical pipeline.
The overall deal value has been adjusted from approximately $2.7 billion to $2.6 billion, with a $105 million reduction in potential future milestone payments.
However, Nanobiotix remains eligible for substantial success-based payments, including up to $1.77 billion in development, regulatory and sales milestones for its first programs, such as cisplatin-ineligible head and neck cancer and unresectable stage 3 non-small cell lung cancer.
Additionally, Johnson &amp; Johnson may develop up to five new indications at its discretion, potentially adding another $650 million in milestone payments.
Nanobiotix also retains eligibility for $165 million in milestone payments across China, South Korea, Singapore and Thailand. Furthermore, for each new indication developed under Nanobiotix's alignment with Johnson &amp; Johnson, the company could earn up to $220 million in additional milestone payments. Tiered royalties in the low double-digit range, from the low teens to low 20s, remain unchanged.
Financially, the amended agreement extends Nanobiotix's cash runway to mid-2026, with efforts underway to secure additional financing—preferably non-dilutive—to extend it further into 2027.
The company also expects a significant reduction in operational cash burn, as the NANORAY-312 trial previously accounted for a major portion of its expenses.
Price Action: NBTX stock is up 4.48% at $3.50 during the premarket session at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44372525/finvolution-reports-strong-q4-eyes-50-revenue-from-international-markets-by-2030-more" target="_blank" rel="noreferrer noopener">FinVolution Reports Strong Q4, Eyes 50% Revenue From International Markets By 2030 &amp; More</a></li>
</ul>
Photo: Shutterstock

Contracts

NBTX

Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden

Sjögren's disease (SjD)&nbsp;is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments&nbsp;&nbsp;
The Company is actively enrolling patients in the Phase 3 DAFFODIL study&nbsp;&nbsp;
This marks the fourth nipocalimab FDA Fast Track designation
SPRING HOUSE, Pa., March 18, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced that the U.S. Food and Drug Administration (FDA) has granted investigational nipocalimab Fast Track designation (FTD) for the treatment of adult patients with moderate-to-severe Sjögren's disease (SjD), having previously been granted <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4384625-1&amp;h=3568246313&amp;u=https%3A%2F%2Fwww.jnj.com%2Fmedia-center%2Fpress-releases%2Fnipocalimab-is-the-first-and-only-investigational-therapy-granted-u-s-fda-breakthrough-therapy-designation-for-the-treatment-of-adults-living-with-moderate-to-severe-sjogrens-disease&amp;a=Breakthrough">Breakthrough</a>&nbsp;Therapy designation (BTD) for the investigational therapy late last year. Currently, no advanced therapies are approved to treat this disease.
Building upon the BTD, which nipocalimab is the first and only therapeutic to receive for&nbsp;SjD, the U.S. FDA's FTD is also designed to accelerate the delivery of new therapeutics to patients by facilitating the development and expediting the review of drugs that demonstrate the potential to treat serious conditions and help address unmet needs for serious or life-threatening conditions.

Johnson & Johnson Announces That The U.S. FDA Has Granted Investigational Nipocalimab Fast Track Designation For The Treatment Of Adult Patients With Moderate-To-Severe Sjögren's Disease, Having Previously Been Granted Breakthrough Therapy Designation For The Investigational Therapy Late Last Year; No Advanced Therapies Are Approved To Treat This Disease

These large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) shares dipped 20.08%. The company agreed to acquire Photonic IC Testing Company Quantifi Photonics <a href="https://www.benzinga.com//node/44236516" target="_blank" rel="noreferrer noopener">for an undisclosed amount</a>. Analysts cut price <a href="https://www.benzinga.com/quote/ter/analyst-ratings" target="_blank" rel="noreferrer noopener">forecasts for the company</a>.</li>
<li>Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) stock tumbled 16.90%, probably amid economic worries driven by tariffs and trade policies.</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) shares dipped 15.79% amid a decline in <a href="https://www.benzinga.com//node/44287858" target="_blank" rel="noreferrer noopener">Bitcoin due to tariff uncertainty</a>.</li>
<li>SailPoint, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) shares fell 15.19%.</li>
<li>Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) shares decreased 15.04% after Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) decided not to exercise its option to receive a worldwide license to develop, manufacture, and commercialize HexaBody-CD38. Genmab will not <a href="https://www.benzinga.com//node/44221409" target="_blank" rel="noreferrer noopener">pursue further clinical development</a>.</li>
<li>Interactive Brokers Group, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) stock fell 12.52%, probably due to overall market concerns amid tariff uncertainty.</li>
<li>Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) stock plummeted 12.26% after the company cut its first-quarter<a href="https://www.benzinga.com//node/44244750" target="_blank" rel="noreferrer noopener"> revenue and profit guidance</a>.</li>
<li>Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) shares declined 12.16% after the company issued the second quarter and FY25 adjusted EPS guidance, with its midpoint below estimates. Several analysts <a href="https://www.benzinga.com//node/44302063" target="_blank" rel="noreferrer noopener">also revised the price forecast</a>.</li>
<li>Expedia Group Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) stock fell 12.05%, probably amid a broader sell-off in travel-related stocks <a href="https://www.benzinga.com//node/44259915" target="_blank" rel="noreferrer noopener">following </a><a href="https://www.benzinga.com//node/44259915" target="_blank" rel="noreferrer noopener">Delta Air Lines&#8217;s</a><a href="https://www.benzinga.com//node/44259915" target="_blank" rel="noreferrer noopener"> guidance cut</a>.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) shares dipped 11.66%. The company announced <a href="https://www.benzinga.com//node/44252567" target="_blank" rel="noreferrer noopener">operating data for February</a>.</li>
<li>United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) stock was down 11.11% after B of A Securities and Barclays cut their <a href="https://www.benzinga.com/quote/ual/analyst-ratings" target="_blank" rel="noreferrer noopener">respective price forecast on the stock</a>.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) stock fell 10.70% last week amid overall market weakness due to continued tariff uncertainty.</li>
</ol>
Photo by Useacoin on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44347715/applovin-super-micro-computer-and-intel-among-top-10-large-cap-gainers-last-week-mar-10-mar-14-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Applovin, Super Micro Computer And Intel Among Top 10 Large-Cap Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?</a></li>
</ul>

Coinbase, Apple And Robinhood Are Among Top Large-Cap Losers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio?

A lawsuit has been lodged against&nbsp;JPMorgan Chase &amp; Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) by its employees, who claim that the company&#8217;s prescription drug plan, overseen by&nbsp;CVS Health Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), consented&nbsp;to pay exorbitant prices for&nbsp;medications.
What Happened: According to a report, the lawsuit alleges that JPMorgan mishandled health benefits. One example cited in the case shows the plan paying over&nbsp;$6,000 for a multiple sclerosis&nbsp;drug that could be purchased for approximately $30 at retail pharmacies. 
The plaintiffs, which&nbsp;include one current and two&nbsp;former employees, contend that this &#8220;systematic mismanagement&#8221; resulted in &#8220;grossly inflated&#8221; medication costs for those enrolled in the plan.
According to the report <a href="https://www.bloomberg.com/news/articles/2025-03-13/jpmorgan-employee-lawsuit-says-bank-overpaid-for-prescription-drugs?sref=TBDibEcD">by</a> Bloomberg, this lawsuit is part of an emerging pattern of similar cases against major employers such as Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) and Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>).
These cases are examining the role of employers in the escalating healthcare costs in the US and&nbsp;the profits of pharmacy benefit&nbsp;managers like CVS.
Also Read: <a href="https://www.benzinga.com/news/25/01/43076952/heres-the-jaw-dropping-total-jpmorgan-chase-paid-to-fight-legal-battles-over-two-years">Here&#8217;s The Jaw-Dropping Total JPMorgan Chase Paid To Fight Legal Battles Over Two Years</a>
The lawsuit alleges that JPMorgan&nbsp;breached its fiduciary duties under&nbsp;the Employee Retirement Income Security&nbsp;Act, which regulates large employers&#8217; benefit plans. The case also highlights instances where JPMorgan&#8217;s&nbsp;plan from CVS Health had&nbsp;significantly&nbsp;higher prices than what patients&nbsp;would pay without insurance.
As of now, JPMorgan has not responded to requests for comment, and a CVS spokesperson declined to comment. The case,&nbsp;Seth Stern et al v.&nbsp;JPMorgan Chase &amp; Co. et al, 25-cv-02097, has been&nbsp;filed in the Southern District&nbsp;of New York.
Why It Matters:&nbsp;This lawsuit underscores the ongoing debate about the role of employers and pharmacy benefit managers in the rising costs of healthcare in the US. 
The outcome of this case could potentially influence how other companies manage their employee health benefits, particularly in relation to prescription drug costs. 
It also raises questions about the transparency and fairness of pricing in the pharmaceutical industry.
Read Next
<a href="https://www.benzinga.com/news/23/11/35865043/us-banks-are-abruptly-freezing-accounts-heres-how-you-can-save-yours" target="_blank" rel="noreferrer noopener">US Banks Are Abruptly Freezing Accounts — Here's How You Can Save Yours</a>
Image: Shutterstock

Allegations of Inflated Prescription Drug Costs Spark Employee Lawsuit Against JPMorgan

Guggenheim analyst Vamil Divan reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from Neutral to Neutral.

Reiteration

Guggenheim Reiterates Neutral on Johnson & Johnsonto Neutral

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$35.00</td>
<td>$43.0K</td>
<td>680</td>
<td>1.7K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/14/25</td>
<td>$815.00</td>
<td>$26.5K</td>
<td>38</td>
<td>268</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$62.50</td>
<td>$125.9K</td>
<td>90</td>
<td>253</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$360.00</td>
<td>$119.2K</td>
<td>472</td>
<td>203</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$210.00</td>
<td>$95.5K</td>
<td>290</td>
<td>193</td>
</tr>
<tr>
<td>IQV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$180.00</td>
<td>$200.2K</td>
<td>31</td>
<td>111</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$490.00</td>
<td>$99.7K</td>
<td>92</td>
<td>77</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$165.00</td>
<td>$26.6K</td>
<td>6.1K</td>
<td>56</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$330.00</td>
<td>$80.8K</td>
<td>14</td>
<td>29</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$600.00</td>
<td>$101.9K</td>
<td>0</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 37 day(s) on April 17, 2025. This event was a transfer of 426 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $43.0K, with a price of $101.0 per contract. There were 680 open contracts at this strike prior to today, and today 1750 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be neutral, expiring in 3 day(s) on March 14, 2025. This event was a transfer of 20 contract(s) at a $815.00 strike. The total cost received by the writing party (or parties) was $26.5K, with a price of $1325.0 per contract. There were 38 open contracts at this strike prior to today, and today 268 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a put option sweep that happens to be bearish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 221 contract(s) at a $62.50 strike. This particular put needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $125.9K, with a price of $570.0 per contract. There were 90 open contracts at this strike prior to today, and today 253 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option trade that happens to be bearish, expiring in 10 day(s) on March 21, 2025. This event was a transfer of 200 contract(s) at a $360.00 strike. The total cost received by the writing party (or parties) was $119.2K, with a price of $596.0 per contract. There were 472 open contracts at this strike prior to today, and today 203 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a put option sweep that happens to be bullish, expiring in 31 day(s) on April 11, 2025. This event was a transfer of 193 contract(s) at a $210.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $95.5K, with a price of $495.0 per contract. There were 290 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding IQV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>), we observe a put option sweep with bullish sentiment. It expires in 283 day(s) on December 19, 2025. Parties traded 110 contract(s) at a $180.00 strike. This particular put needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $200.2K, with a price of $1820.0 per contract. There were 31 open contracts at this strike prior to today, and today 111 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be bullish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 23 contract(s) at a $490.00 strike. The total cost received by the writing party (or parties) was $99.7K, with a price of $4335.0 per contract. There were 92 open contracts at this strike prior to today, and today 77 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a call option trade with bullish sentiment. It expires in 101 day(s) on June 20, 2025. Parties traded 35 contract(s) at a $165.00 strike. The total cost received by the writing party (or parties) was $26.6K, with a price of $760.0 per contract. There were 6139 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 26 contract(s) at a $330.00 strike. The total cost received by the writing party (or parties) was $80.8K, with a price of $3110.0 per contract. There were 14 open contracts at this strike prior to today, and today 29 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with neutral sentiment. It expires in 464 day(s) on June 18, 2026. Parties traded 10 contract(s) at a $600.00 strike. The total cost received by the writing party (or parties) was $101.9K, with a price of $10193.0 per contract. There were 0 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

VKTX

10 Health Care Stocks Whale Activity In Today's Session

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Exxon Mobil, Johnson &amp; Johnson, and Cogent Communications have rewarded shareholders for years and recently announced dividend increases. These companies currently offer dividend yields of up to 5%.
Exxon Mobil&nbsp;
Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) engages in the exploration and production of crude oil and natural gas in the U.S. and internationally.
Exxon Mobil has raised its dividends every year for the last 42 years. According to its most recent dividend hike announcement on Nov. 1, the company increased the quarterly payout by 4% to $0.99 per share, which is equal to an annual figure of $3.96 per share. The current dividend yield is 3.76%.
Don't Miss:
<ul>
<li>It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
<li>Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"> investors with $1M+ in DOGE revealed!</a></li>
</ul>
Exxon Mobil&#8217;s annual revenue as of Dec. 31 stood at $339.25 billion. In its Q4 2024 earnings release on Jan. 31, the company posted quarterly revenues of $83.43 billion, missing the consensus estimate of $87.20 billion, while EPS of $1.67 came in above the consensus of $1.55.&nbsp;
If you invested $10,000 in Exxon Mobil stock 10 years ago, how much would you have now? Check out this <a href="https://www.benzinga.com/markets/25/01/43308384/if-you-invested-10-000-in-exxon-mobil-stock-10-years-ago-how-much-would-you-have-now">article by Benzinga</a> to learn more.
Johnson &amp; Johnson
Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
Johnson &amp; Johnson has increased its dividends consecutively for the last 62 years. In its most recent dividend hike announcement on April 16, the company's board raised the quarterly payout by 4.2% to $1.24 per share, equal to an annual figure of $4.96 per share. Currently, the dividend yield on the stock is 3.00%.
Trending: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Johnson &amp; Johnson&#8217;s annual revenue as of Dec. 31 stood at $88.82 billion. As per the company's Q4 2024 earnings report on Jan. 22, it posted revenues of $22.52 billion and EPS of $2.04. Both figures came in above the consensus estimates.
Check out this <a href="https://www.benzinga.com/insights/analyst-ratings/25/03/44151435/what-14-analyst-ratings-have-to-say-about-johnson-johnson">article by Benzinga</a> for 14 analysts' insights on Johnson &amp; Johnson.
Cogent Communications
Cogent Communications Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NASDAQ">CCOI</a>) provides high-speed Internet access, private network, and data center colocation space services in North America, South America, Europe, Oceania, and Africa.
Cogent Communications has increased its dividend consecutively for the last 13 years. As per the company's most recent dividend announcement on Feb. 27, its board of directors raised the quarterly payout by $0.01 to $1.005 per share, which is equal to an annual figure of $4.02 per share. The dividend yield currently stands at 5.72%.
See Also: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.
The company's annual revenue as of Dec. 31 stood at $1.04 billion. In its most recent earnings report on Feb. 27, it posted Q4 2024 revenues of $252.29 million, missing expectations, while the per-share loss of $0.91 came in better than feared.&nbsp;
Exxon Mobil, Johnson &amp; Johnson, and Cogent Communications are good choices for investors seeking reliable passive income. Their dividend yields of up to 5% and long history of consistent hikes make them attractive to income-focused investors.
Read Next:
<ul>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>

Personal Finance

CCOI

How Exxon Mobil, Johnson & Johnson, And Cogent Communications Can Put Cash In Your Pocket

Press Releases

Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients

Health Canada authorizes LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer

Six Dean Omar Branham Shirley Partners Honored for Representation of Plaintiffs

Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025

U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease

Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years

Management

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer

TVGN

TVGNW

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

B of A Securities

RBC Capital

Barclays

Morgan Stanley

Stifel

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

Comments

Johnson & Johnson

뉴스

파트너 / 기고자

벤징가 글로벌